August 4th 2022
Fresenius Kabi expects to receive FDA approval for its tocilizumab biosimilar in 2023 and is seeking approval in both intravenous and subcutaneous administration.
August 4th 2022
Results indicated the trial is unlikely to meet its primary endpoint, the change from baseline in the six-minute walk test at 24 weeks.
August 4th 2022
The new code, effective Oct. 1, 2022, allows APDS to be recognized as an distinct immunological disease.
August 4th 2022
This is the second trial in less than a month studying Keytruda that failed to meet endpoints.
August 3rd 2022
OptumRx profiles four therapies that are expecting FDA decisions in the next few months.